Are there any domestically produced drugs for Gilteritinib?

Gilteritinib has been approved for use in newly diagnosed AML (acute myeloid leukemia) patients, specifically those carrying FLT3-ITD or FLT3-TKD gene mutations. The goals of treating newly diagnosed AML are to achieve remission, prolong disease progression-free survival (Progression-Free Survival, PFS) and improve overall survival. Giritinib is also approved for patients with relapsed/refractory AML, including those with FLT3-ITD or FLT3-TKD gene mutations. For these patients, traditional treatments often have limited effectiveness, and giritinib provides a new treatment option.

Currently, giritinib has been launched in China. Only imported original drugs are available, and there is no domestically produced giritinib. It is not included in medical insurance. If patients need it, they can go to the hospital to buy it at their own expense, but the price is very high, about about 35,000 yuan. For specific prices, please consult the local hospital pharmacy.

Foreign original drugs of gilitinib are even more expensive. For example, the Hong Kong version of the original drug costs about 90,000 yuan, and the European version of the original drug costs more than 200,000 yuan, which is simply unaffordable for ordinary patients.

There are already foreign generic drugs of Giritinib on the market, mainly Laos generic drugs, and the price is about 4,000 to 5,000 yuan, which is relatively cheap. In terms of drug ingredients, the ingredients of domestic and foreign original gilitinib drugs are basically the same as those of generic drugs.

It should be noted that giritinib is not suitable for all AML patients, but is mainly used for specific subtypes of AML, namely subtypes with FLT3 gene mutations. Patients should use gilitinib under the supervision of a physician, with a treatment plan based on their specific condition and medical guidance. In summary, giritinib represents an important advance in the treatment of AML for patients with AMLpatients with mutations in the FLT3 gene offer hope and improve their treatment prospects.